2007, Number S2
PDF size: 75.97 Kb.
ABSTRACTThe convenience to count with a safe and effective pharmacological wealth for atrial fibrillation treatment had conduced, in a way, to a deep depuration of the vast array of antiarrhythmic drugs, keeping only a very restricted number of compounds with a widely proved anti-atrial activity. On the other hand, it had lead to the discovery of the pathophysiological concepts that point to novel therapeutic targets. Within these objectives is that new antiarrhythmic drugs with preferential, even selective, activity on myocardial atrium ion channels had been developed. Among these new antiarrhythmics, dofetilide, and AVE0118, are taken into account. In addition, new possibilities are opened based on the knowledge of the cardioprotective-antiarrhythmic qualities of the opioidergic system.
Cárdenas Loaeza M: Clínica de las arritmias. La Prensa Médica Mexicana, 1976.
Vaughan Williams EM: Classifying antiarrhythmic actions by fact or speculation. J Clin Pharmacol 1992; 32: 964-977.
Ruskin JN: The cardiac arrhythmia suppression trial CAST. New Engl J Med 1989; 321: 386-388.
Walker MJA: Antiarrhythmic drug research. Br J Pharmacol 2006; 147: S222-S231.
Gaborit N, Steenman M, Lamirault G, Le Meur N, Le Bouter S, et al: Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation 2005; 112: 471-481.
Wang Z, Fermini B, Nattel S: Sustained depolarization-induced outward current in human atrial myocytes: evidence for a novel delayed rectifier K current similar to Kv1.5 cloned channel currents. Circ Res 1993; 73: 1071-1076.
Singh S, Zoble RG, Yellen E: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385-2390.
Stambler BS, Wood MA, Ellenbogen KA: Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613-1621.
Lishmanov YB, Maslov LN: Opioid receptors and heart resistance to arrhythmogenic factors. Bull Exp Biol Med 2004; 138: 107-112.
Xiao GS, Zhou JJ, Wang GY, Cao CM, Li GR, Wong TM. In vitro electrophysiologic effects of morphine in rabbit ventricular myocytes. Anesthesiology 2005; 103: 280-286.